Vedolizumab Approval Supported, But Committee Differs on Indicated Population
This article was originally published in The Pink Sheet Daily
Executive Summary
Entyvio gains recommendation for approval in ulcerative colitis and Crohn’s disease from a joint GI and drug safety advisory committee, but concerns about indicated population may shape use; weather problems forced a shortened meeting.
You may also be interested in...
Patient-Focused Drug Development, Complex Trial Design May Not Get More Funding In PDUFA VII
US FDA proposed increasing staffing and resources for both programs during the next user fee program cycle, but industry representatives did not believe it necessary.
Drug Costs Not A Primary Driver Of Rare Disease Economic Burden
EveryLife Foundation study finds inpatient and outpatient care, not prescription drugs, are the primary excess medical costs associated with rare diseases.
US FDA Still Discussing Ideas For Pediatric Development Of COVID-19 Vaccines
J&J CEO Gorsky says the agency is working with sponsors to ensure the proper data is gathered to make the vaccine available in children.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: